Atlas Trials

An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer

Clinical trial NCT03690141 · TERMINATED

Trial details

NCT number
NCT03690141
Sponsor
Effector Therapeutics
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Castrate-resistant Prostate Cancer (CRPC)
Start date
2018-11-27
Primary completion
2020-04-27
Enrollment
16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.